98%
921
2 minutes
20
Background: Cholangiocarcinomas have a poor prognosis, and resection is the only curative-intent treatment. We examined time-trends in mortality risk after resection in a nationwide Danish cohort.
Methods: We identified all Danish citizens diagnosed with cholangiocarcinoma in 2004-2022 who subsequently underwent liver resection, biliary tract resection, or a combination of the two. We computed the proportions of patients who received downstaging or adjuvant chemotherapy, and we estimated age- and sex-adjusted mortality risks.
Results: Between 2004 and 2022, 611 patients with cholangiocarcinoma underwent resection (13% of 4,572 patients with cholangiocarcinoma). The proportion who underwent resection increased from 9% in 2004-2012 to 16% in 2018-2022, the median age of resected patients rose from 65 to 69 years, and the proportion with comorbidities increased from 17% to 28%. In patients who underwent liver resection, the proportion who had received downstaging chemotherapy increased from < 7% in 2004-2012 to 12% (8-20), and the proportion who received adjuvant chemotherapy increased from 27% (18-39) in 2004-2012 to 49% (40-58) in 2018-2022. Despite the increasing use of chemotherapy before and after liver resection, age- and sex-adjusted mortality remained essentially the same, with 1-year mortality ranging from 14% to 20% (p-value = 0.37). In patients who underwent biliary tract resection, only 3% received downstaging chemotherapy, but the proportion who received adjuvant therapy increased from 17% (10-29) in 2004-2012 to 59% (48-68) in 2018-2022. Even so, these patients' age- and sex-adjusted mortality remained stable (1-year mortality ranging from 19 to 24%, p-value = 0.34).
Conclusion: The proportion of patients with cholangiocarcinoma who underwent liver or biliary tract resection increased, and more patients received downstaging chemotherapy and adjuvant chemotherapy. Nonetheless, age- and sex-adjusted mortality risks remained constant. The explanations for this pattern are unclear but likely involve changing patient characteristics other than age and sex.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/JS9.0000000000003329 | DOI Listing |
Lancet HIV
September 2025
Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA; Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. Electronic address:
Background: Past cohort studies have examined mortality among children and young adolescents (aged 0-14 years) who have received antiretroviral therapy (ART), but no systematic reviews have been undertaken to synthesise these findings. Our study aims to provide the most comprehensive global estimates of paediatric mortality among children and adolescents receiving ART.
Methods: For this systematic review and meta-regression analysis, we searched PubMed and Embase from Jan 1, 1990 to July 31, 2024 for studies reporting mortality among children and young adolescents living with HIV who were on ART.
Int J Surg
September 2025
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Background: Cholangiocarcinomas have a poor prognosis, and resection is the only curative-intent treatment. We examined time-trends in mortality risk after resection in a nationwide Danish cohort.
Methods: We identified all Danish citizens diagnosed with cholangiocarcinoma in 2004-2022 who subsequently underwent liver resection, biliary tract resection, or a combination of the two.
Neurologia (Engl Ed)
September 2025
Unit of Public Health, Prevention and Health Promotion, South Seville Health Management Area, Seville, Spain. Electronic address:
Background: This study aims to update and evaluate the age-period-cohort (A-P-C) effects on stroke mortality in Spain over the period 1982-2021.
Methods: Data on stroke mortality and population by age and sex were obtained from the database of the National Institute of Statistics for the years 1982-2021. Joinpoint trend analysis software from the US National Cancer Institute was used to estimate the rates and their time trends.
Sci Rep
September 2025
Division of Social Determinants of Health, Department of Epidemiology and Health Monitoring, Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany.
Background Cancer is one of the main causes of a high burden of disease and one of the strongest contributors to earlier mortality among lower socioeconomic groups in Germany. Therefore, studying socio-economic inequalities in cancer incidence is of high relevance from a public-health and health-equity lens. The aim of this study was to examine in more depth time trends in socioeconomic inequalities in cancer incidence and the related potential for reducing the incidence of specific cancers across Germany.
View Article and Find Full Text PDFBMC Public Health
August 2025
Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, 51-618, Wroclaw, Poland.
Background: Cardiovascular diseases (CVDs) are the leading cause of mortality globally and in Poland. This study assessed the prevalence and trends of cardiovascular (CV) risk factors in the Polish population over time.
Methods: Data from 705,399 individuals aged 35-55 years enrolled in a CVD prevention program (2012-2021) were analyzed.